← Leaderboards
Joseph Reginald Osborne
Weill Medical Coll Of Cornell Univ
$1,156,787
Attributed
$2,094,468
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $575.5K · FY2011–18$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,094,468 · 2
By mechanism
R01$1,690,135 · 1
R21$404,333 · 1
Top collaborators
- Balu Easwaramoorthy3 shared
- Wolfgang Weber1 shared
Others in their field
Top investigators on “Metastatic Prostate Cancer”
- David Heimbrook · Leidos Biomedical Research, Inc.$86,155,371
- Walter John Curran · Thomas Jefferson University$26,641,549
- Arul M Chinnaiyan · University Of Michigan At Ann Arbor$20,468,199
- Larry Arthur$17,525,000
- Cory Abate-Shen · Columbia University Health Sciences$16,894,858
- Daniel B Vigneron · University Of California, San Francisco$15,322,932
Research focus
Metastatic Prostate CancerTumorImageMalignant Neoplasm Of ProstateRadioisotopesSmall MoleculeDesignEvaluationInhibitor/AntagonistLabelMonitorPositron-Emission TomographyRadiopharmaceuticalsResponseAffectBaseDoseBiodistributionClinical TrialsImaging TechniquesClinicIn VitroMolecular ImagingUptake
Grant awards (5)
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use$575,548
R01 · FY2018 · CA · contact PI
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use$558,907
R01 · FY2017 · CA · contact PI
A new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use$555,680
R01 · FY2016 · CA
Immuno-PET With Anti-PSMA 89Zr-J591 mAb For Molecular Imaging of Prostate Cancer$183,788
R21 · FY2012 · CA · contact PI
Immuno-PET With Anti-PSMA 89Zr-J591 mAb For Molecular Imaging of Prostate Cancer$220,545
R21 · FY2011 · CA · contact PI